Navigation Links
INVO Bioscience Announces Planned Submission To ANVISA For Brazilian Approval Following Completion of Clinical Trial
Date:6/14/2011

nd now Brazil, while continuing to explore additional appropriate countries to begin the registration process to market its products.

About INVO Bioscience

INVO Bioscience (IVOB) is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit www.invobioscience.com.

About The Center of Infertility and Fetal Medicine of North Rio de Janeiro

The Center for Fetal Medicine and Infertility is associated with the Hospital of the Medicine College of Campos in the state of Rio de Janeiro in partnership with local government offering services to couples for the public health system. The Infertility Center was the first laboratory to obtain certification from ANVISA as well as offered the first agreement for public assistance (free) in the state of Rio de Janeiro.

Private Securities Litigation Reform Act of 1995

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan
'/>"/>

SOURCE INVO Bioscience, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Avantra Biosciences Announces Significant Reduction In Multiplex Immunoassay Processing Time
2. Avantra Biosciences Announces the Launch of a Rapid Assay Prototyping Service
3. GeneLink Biosciences Expands its Scientific Advisory Board to Support New Product Lines
4. Ardea Biosciences to Present at Upcoming Investor Conferences
5. Health Diagnostic Laboratory, Inc. (HDL, Inc.) Receives the Virginia Bioscience Company of the Year Award
6. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
7. Magellan Biosciences to Present at Medicaid Health Plans of America Center for Best Practices First Annual Awards Forum
8. TEI Biosciences Wins SBANE 2011 New England Innovation Award
9. Transposagens piggyBac™ Vectors to be Distributed by System Biosciences
10. Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results
11. Cell Biosciences Announces Issuance of Three US Patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... LAVAL, QC, June 4 /PRNewswire-FirstCall/ - Neptune Technologies & ... it has signed an agreement with Bayer Healthcare, LLC ... United States. , "The signing of this agreement with ... business and scientific choice to pursue the more demanding ...
... June 4 Santaris Pharma today announced that,the cancer ... by,Enzon Pharmaceuticals and Santaris Pharma A/S - was well ... treated cancer patients with,advanced malignancies. EZN-2968 is being evaluated ... which was presented at the 2009 American,Society of Clinical ...
... OPTR ) today announced that the Company will present at the following investor ... 8th Annual Needham Life Sciences Conference on Wednesday, June 10, ... New York City. , Jefferies, 3rd Annual ... the Mandarin Oriental Hotel in New York City. , ...
Cached Biology Technology:Neptune Products to be commercialized by BAYER HealthCare 2Neptune Products to be commercialized by BAYER HealthCare 3LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs of Clinical Benefit 2LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs of Clinical Benefit 3Optimer Pharmaceuticals to Present at June 2009 Investor Conferences 2
(Date:12/15/2014)... , Dec. 12, 2014 Research and ... the addition of the "Global Facial Recognition ... http://photos.prnewswire.com/prnh/20130307/600769 ... identification of individuals. Facial recognition system measures the ... nose, jaw edges, mouth, and the distance between ...
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... in wireless physiologic monitoring, has released a new ... changing needs of preclinical toxicology researchers. M series, ... to help toxicologists collect the best possible physiologic ... studies. Adding functional endpoints to toxicology ...
(Date:12/10/2014)... -- CIE San Diego has launched an innovative trust ... that enhances care coordination among social service and care ... earned a second $1 million grant from the Alliance ... in community and; will be recognized as a "Live ... 4-6p. CIE San Diego today announced the ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... of spinal cord injuries among senior citizens (age 70 and ... as compared with younger spinal cord injury patients, researchers at ... Center of the Delaware Valley recently reported. , As the ... 20 percent of its population will be older than age ...
... Systematic Review of the use of electronic mosquito repellents (EMRs) ... therefore say that there is no reason for recommending their ... to do more research with the devices. , Malaria is ... mosquito. Manufacturers of electronic mosquito repellents (EMRs) claim that the ...
... and zanamivir, are highly effective when given as ... the influenza virus, according to an analysis of ... Research Center, University of Michigan and University of ... the American Journal of Epidemiology. The analysis also ...
Cached Biology News:Elderly spinal cord injuries increase five-fold in 30 years, Jefferson neurosurgeons find 2Antivirals effectively curb influenza virus 2Antivirals effectively curb influenza virus 3
Human FADD Affinity Purified Polyclonal Ab...
Human VEGF R3/Flt-4 Phycoerythrin MAb (Clone 54733)...
Immunogen: Synthetic Peptide: V(22) N G H E F E I E G E G E G R(36) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Human beta IG-H3 MAb (Clone 348506) Keywords: BIGH3, betaIG-H3 Protein Family: Extracellular Matrix Molecules...
Biology Products: